Completed PHASE4 INTERVENTIONAL 2-arm NCT02491008

Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction (TRUST BONE)

Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction: a Prospective Evaluation and Impact of Treatment

Sponsor: Insel Gruppe AG, University Hospital Bern

Conditions Bone Mineral Density Fractures, Bone Osteoporosis Thyroid Dysfunction

Interventions Levothyroxine Placebo

Updated 7 times since 2017 Last updated: Jan 31, 2017 Started: Jan 31, 2014 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Bone Mineral Density and Fractures, Bone and is currently completed. Insel Gruppe AG, University Hospital Bern leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jul 2023 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2023 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Insel Gruppe AG, University Hospital Bern
University of Lausanne Hospitals

Data source: Insel Gruppe AG, University Hospital Bern

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bern, Switzerland
• Lausanne, Switzerland